[1] POWERS W J，RABINSTEIN A A，ACKERSON

T，et al. Guidelines for the early management of

patients with acute ischemic stroke：2019 update

to the 2018 guidelines for the early management of

acute ischemic stroke：a guideline for healthcare

professionals from the American Heart Association/

American Stroke Association[J/OL]. Stroke，2019，50

（12）：e344-e418[2020-07-15]. https：//doi.org/10. 1161/

STR.0000000000000211.

[2] ZERNA C，THOMALLA G，CAMPBELL B C V，et al.

Current practice and future directions in the diagnosis

and acute treatment of ischaemic stroke[J]. Lancet，

2018，392（10154）：1247-1256.

[3] KIRMANI J F，ALKAWI A，PANEZAI S，et al.

Advances in thrombolytics for treatment of acute

ischemic stroke[J/OL]. Neurology，2012，79（13 Suppl

1）：S119-S125[2020-07-15]. https：//doi.org/10.1212/

WNL.0b013e3182695882.

[4] ADIVITIYA，KHASA Y P. The evolution of recombinant

thrombolytics：current status and future directions[J].

Bioengineered，2017，8（4）：331-358.

[5] KUMAR A，PULICHERLA K K，SEETHA K，et al.

Evolutionary trend of thrombolytic -- their significance[J].

International Journal of Bio-Science and Bio-Technology，

2011，3（1）：1-17.

[6] 中华医学会神经病学分会，中华医学会神经病学分会脑血

管病学组. 中国急性缺血性脑卒中诊治指南2014[J]. 中华神

经科杂志，2015，48（4）：246-257.

[7] WARDLAW J M，MURRAY V，BERGE E，et al.

Recombinant tissue plasminogen activator for acute

ischaemic stroke：an updated systematic review and metaanalysis[

J]. Lancet，2012，379（9834）：2364-2372.

[8] The National Institute of Neurological Disorders and

Stroke rt-PA Stroke Study Group. Tissue plasminogen

activator for acute ischemic stroke[J]. N Engl J Med，1995，

333（24）：1581-1587.

[9] HACKE W，KASTE M，FIESCHI C，et al. Intravenous

thrombolysis with recombinant tissue plasminogen

activator for acute hemispheric stroke. The European

Cooperative Acute Stroke Study（ECASS）[J]. JAMA，

1995，274（13）：1017-1025.

[10] HACKE W，KASTE M，FIESCHI C，et al. Randomised

double-blind placebo-controlled trial of thrombolytic

therapy with intravenous alteplase in acute ischaemic stroke

（ECASS Ⅱ）. Second European-Australasian Acute Stroke

Study Investigators[J]. Lancet，1998，352（9136）：1245-

1251.

[11] CLARK W M，ALBERS G W，MADDEN K P，et al. The

rtPA（alteplase）0- to 6-hour acute stroke trial，part A

（A0276g）：results of a double-blind，placebo-controlled，

multicenter study. Thromblytic therapy in acute ischemic

stroke study investigators[J]. Stroke，2000，31（4）：811-

816.

[12] CLARK W M，WISSMAN S，ALBERS G W，et al.

Recombinant tissue-type plasminogen activator（alteplase）

for ischemic stroke 3 to 5 hours after symptom onset. The

ATLANTIS study：a randomized controlled trial. Alteplase

thrombolysis for acute noninterventional therapy in

ischemic stroke[J]. JAMA，1999，282（21）：2019-2026.

[13] ALBERS G W，CLARK W M，MADDEN K P，et al.

ATLANTIS trial：results for patients treated within 3

hours of stroke onset. Alteplase thrombolysis for acute

noninterventional therapy in ischemic stroke[J]. Stroke，

2002，33（2）：493-495.

[14] HACKE W，KASTE M，BLUHMKI E，et al. Thrombolysis

with alteplase 3 to 4.5 hours after acute ischemic stroke[J].

N Engl J Med，2008，359（13）：1317-1329.

[15] DAVIS S M，DONNAN G A，PARSONS M W，et

al. Effects of alteplase beyond 3 h after stroke in the

Echoplanar Imaging Thrombolytic Evaluation Trial

（EPITHET）：a placebo-controlled randomised trial[J].

Lancet Neurol，2008，7（4）：299-309.

[16] IST-3 collaborative group，SANDERCOCK P，WARDLAW

J M，et al. The benefits and harms of intravenous

thrombolysis with recombinant tissue plasminogen

activator within 6 h of acute ischaemic stroke（the third

International Stroke Trial[IST-3]）：a randomised controlled

trial[J]. Lancet，2012，379（9834）：2352-2363.

[17] ANDERSON C S，ROBINSON T，LINDLEY R I，et al.

Low-dose versus standard-dose intravenous alteplase in

acute ischemic stroke[J]. N Engl J Med，2016，374（24）：

2313-2323.

[18] THOMALLA G，SIMONSEN C Z，BOUTITIE F，et al.

MRI-guided thrombolysis for stroke with unknown time of

onset[J]. N Engl J Med，2018，379（7）：611-622.

[19] MA H，CAMPBELL B C V，PARSONS M W，et al.

Thrombolysis guided by perfusion imaging up to 9 hours

after onset of stroke[J]. N Engl J Med，2019，380（19）：

1795-1803.

[20] COUTTS S B，BERGE E，CAMPBELL B C，et al.

Tenecteplase for the treatment of acute ischemic stroke：a

review of completed and ongoing randomized controlled

trials[J]. Int J Stroke，2018，13（9）：885-892.

[21] ZITEK T，ATAYA R，BREA I. Using tenecteplase for

acute ischemic stroke：what is the hold up?[J]. West J

Emerg Med，2020，21（2）：199-202.

[22] HALEY E C Jr，LYDEN P D，JOHNSTON K C，et al. A

pilot dose-escalation safety study of tenecteplase in acute

ischemic stroke[J]. Stroke，2005，36（3）：607-612.

[23] PARSONS M，SPRATT N，BIVARD A，et al. A

randomized trial of tenecteplase versus alteplase for acute

ischemic stroke[J]. N Engl J Med，2012，366（12）：1099-

1107.

[24] HUANG X Y，CHERIPELLI B K，LLOYD S M，et

al. Alteplase versus tenecteplase for thrombolysis after

ischaemic stroke（ATTEST）：a phase 2，randomised，

open-label，blinded endpoint study[J]. Lancet Neurol，2015，

14（4）：368-376.

[25] LOGALLO N，NOVOTNY V，ASSMUS J，et al.

Tenecteplase versus alteplase for management of acute

ischaemic stroke（NOR-TEST）：a phase 3，randomised，

open-label，blinded endpoint trial[J]. Lancet Neurol，2017，

16（10）：781-788.

[26] CAMPBELL B C V，MITCHELL P J，CHURILOV L，et

al. Tenecteplase versus alteplase before thrombectomy for

ischemic stroke[J]. N Engl J Med，2018，378（17）：1573-

1582.

[27] CAMPBELL B C V，MITCHELL P J，CHURILOV L，et

al. Effect of intravenous tenecteplase dose on cerebral

reperfusion before thrombectomy in patients with large

vessel occlusion ischemic stroke：the EXTEND-IA TNK

Part 2 randomized clinical trial[J]. JAMA，2020，323（13）：

1257-1265.